Corrections or additions?
This article by Barbara Fox was prepared for the September 18, 2002 edition of U.S. 1 Newspaper. All rights reserved.
Technology Who’s Who
<B>Geoffrey M. Nichol has left Novartis Pharmaceuticals
Corporation to be senior vice president of product development at
Medarex Inc. on Route 206. At SmithKline Beecham Pharmaceuticals (now
GlaxoSmithKline) he was involved in the development and commercialization
of the antibiotic product, Augmentin.
At Novartis he had been head of global project management, vice president
and head of U.S. medical affairs, and vice president and head of respiratory,
bone, and HRT clinical research.
Nichol has an MD from University Medical School in New Zealand, and
an MBA from Warwick University in the United Kingdom. With the UltiMAb
Human Antibody Development System, Medarex develops monoclonal antibody-based
therapeutics for cancer and other diseases,
consulting service, has received approval and allowance of his claim
for a patent on a transdermal method of diagnosing and treating AIDS,
hepatitis, cancer, and other infection diseases. He and his associate,
William R. Levis, attending dermatologist at New York Medical
Center, are ready to begin clinical studies at the Bellevue Medical
"Our product is a generalized immune system stimulant that will
be of value for the diagnosis and treatment of AIDS, hepatitis, Epstein
Barr syndrome, and other viral infections — any situation where
the immune system is compromised," says Kaplan. "It will boost
the immune system, the T-lymphocyte (CD4, CD8) and natural killer
cells, through the dendritic antigen presenting cells — in order
to combat infection without use of outside agents such as interferons."
His company, Pharmaceutical Quality Associates at 20 Nassau Street
(609-683-9484), offers consulting services and product development
for innovative oral and topical drug delivery systems. A native New
Yorker, Kaplan earned his pharmacy degree from Ohio State in 1952
and has a PhD from New York University. After working for Richardson
Vicks he joined Johnson & Johnson, where he was vice president of
research in the Advanced Care Products division. He later worked with
Sterling Winthrop Research in Rensselaer, New York.
AIDS research is shifting dramatically from high activity antiretroviral
therapy to immune system stimulation of immunocompromised patients,
says Kaplan. His patented transdermal compositions contain a safe
and effective delayed sensitizer drug that induces stimulation of
cell-mediated immune responses in responsive patients. AIDS will be
the first FDA-approved use for this treatment, followed by hepatitis,
which often accompanies HIV infections.
"I just had an inquiry from Korea regarding Hepatitis B, an epidemic
sexual transmitted disease," says Kaplan. "Dr. Levis and I
are funding it ourselves through my company here. We are very excited
— Barbara Fox
Corrections or additions?
This page is published by PrincetonInfo.com
— the web site for U.S. 1 Newspaper in Princeton, New Jersey.